Source-grounded facts extracted from Janux Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Janux Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-11 meeting.
“Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,749,182 4,574,376 46,341 6,375,023”
Janux Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-11 meeting.
“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 53,560,969 113,446 70,507”
Janux Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.
“Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Natasha Hernday 42,850,103 4,519,796 6,375,023 Eric Dobmeier 46,279,387 1,090,512 6,375,023”
Janux Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $24.4 million for the quarter ended March 31, 2026.
“Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.”
Janux Therapeutics, Inc. entered into Collaboration Agreement with Bristol-Myers Squibb Company valued at upfront payment of $15 million (effective 2026-01-21).
“On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types (the “Collaboration Target”).”
Eric Dobmeier was appointed as Class III Director at Janux Therapeutics, Inc..
“and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.”
Natasha Hernday was appointed as Class II Director at Janux Therapeutics, Inc..
“On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.”
Ron Barrett was appointed as Chair of the Board at Janux Therapeutics, Inc..
“In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.”
Jay Lichter resigned as Director and Chairman at Janux Therapeutics, Inc..
“On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.”
Janux Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss of $14.8 million.
“Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.”
Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023.
“Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
Janux Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $11.6 million.
“Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights”
Janux Therapeutics, Inc. reported financial results for the six months ended June 30, 2023.
“Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
Janux Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $17.5 million.
“Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
Janux Therapeutics, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the underwriters named in Schedule A therein valued at $60 million (effective 2023-07-17).
“On July 17, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Offering”) by the Company of (i) 4,153,717 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $12.46 per share, and (ii) pre-funded warrants to purchase 583,483 shares of Common Stock at a price of $12.459 per pre-funded warrant (the “Pre-Funded Warrants”), which represents the per share price for the Shares less a nominal $0.001 per share exercise price for each Pre-Funded Warrant. Gross proceeds from the Offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million.”
Byron Robinson was appointed as interim head of clinical activities at Janux Therapeutics, Inc..
“On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.”
Wayne Godfrey resigned as Chief Medical Officer at Janux Therapeutics, Inc..
“On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.”
Janux Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 34,536,553 155,699 245”
Janux Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-14 meeting.
“Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Sheila Gujrathi, M.D. 25,697,774 8,374,247 620,476 Alana McNulty 31,885,716 2,186,305 620,476”
Janux Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1)).
“June 16, 2023 acknowledging the Company’s non-compliance with Listing Rule 5605(b)(1). The letter from Nasdaq further provided that, consistent with Listing Rule 5605(b)(1)(A), Nasdaq will provide the Company a cure period in order to regain compliance with Listing Rule 5605(b)(1). The cure period will end on the earlier of (i) the Company’s next annual meeting of stockholders or (ii) June 14, 2024 (unless such next annual meeting is held prior to December 11, 2023, in which case the cure period will end on December 11, 2023). The Board is evaluating options to achieve compliance within the cu”
Janux Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. valued at up to $150.0 million (effective 2023-05-09).
“On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an ATM Equity OfferingSM Sales Agreement (the “Agreement”) with BofA Securities, Inc. (“BofA”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million”
Janux Therapeutics, Inc. reported the three months ended March 31, 2023 results: net income net loss of $17.5 million.
“On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023.”
Peter Thompson departed as director at Janux Therapeutics, Inc..
“On March 27, 2023, Peter Thompson, M.D., a director of Janux Therapeutics, Inc. (the “Company”), informed the Company that he does not intend to stand for re-election as a member of the Board of Directors at the Company’s 2023 annual meeting of stockholders as a result of competing commitments.”
Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $16.1 million for the quarter and $63.1 million for the year ended December 31, 2022.
“Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.”
Janux Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2022.
“On November 10, 2022, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”
Stefan Heller resigned as Director at Janux Therapeutics, Inc..
“Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.”
Winston Kung was appointed as Class I director at Janux Therapeutics, Inc..
“On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company”
Alana McNulty was appointed as Class II director at Janux Therapeutics, Inc..
“appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.”
Ronald Barrett was appointed as Class I director at Janux Therapeutics, Inc..
“appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.